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Abstract: Ischemic preconditioning (IPC) is a well-documented phenomenon. Short episodes of sublethal ischemia provide cardio-
protective effects for subsequent longer duration ischemic events. Although the exact mechanism of IPC is not yet known, the chemi-
cal basis of IPC seems to involve preservation of ATP or collateral vascularization recruitment. In this case report, we present visual 
evidence of ischemic preconditioning using Heartscape Technologies 80 Lead ECG device. The 80 Lead ECG is described as a body 
surface mapping modality, converting its inputted 80 lead ECG data into a 3-Dimensional color coded map. The 80 lead ECG device 
can detect instantaneous ischemic changes. Different studies have been performed to show different clinical and biochemical aspects 
of IPC. However data regarding direct visual evidence of this phenomenon is lacking. The secondary objective of this study is to show 
the ability of 80 lead ECG to identify ST-segment elevation and depression during ischemic events. The utility of 80 Lead ECG body 
surface mapping is enormous when evaluating ischemic events.
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Introduction
Ischemic  preconditioning  (IPC)  is  a  phenomenon 
  during which transient sub lethal episodes of ischemia 
before a prolonged ischemia/reperfusion injury pro-
vide cardioprotection for subsequent longer duration 
ischemic events.1 Hearts exposed to IPC have a better 
metabolic and ionic status during prolonged ischemia 
compared to naive hearts.2 Recent studies in surgical 
models of cardioplegic arrest and reperfusion have 
suggested that the preconditioned, arrested heart may 
have an increased tolerance to prolonged ischemia and 
improved functional recovery after reperfusion.3 The 
initial ischemic event activates numerous signal trans-
duction pathways, which serve to maintain myocyte 
contractility and function.4 Experimentally, a reduc-
tion in myocardium infarct size can be induced by 
subjecting the heart to episodes of non-lethal myocar-
dial ischaemia and reperfusion prior to the sustained 
coronary artery occlusion.5 In-hospital risk of adverse 
events, the risk of death, and non fatal myocardial 
infarction (MI) are reduced significantly in patients 
experiencing IPC. Failure of IPC production during 
percutaneous coronary intervention (PCI), serves as 
an independent predictor of future ischemic event.6 
Different studies have been performed to show differ-
ent clinical and biochemical aspects of IPC. However 
data regarding direct visual evidence of this phenom-
enon is lacking. Also, there are not many studies on 
the use of 80 lead ECG to evaluate ischemic events. 
In this case report, we present the visual evidence of 
IPC,  using  Heartscape  Technologies  80  lead  ECG 
device, a body surface mapping modality that con-
verts 80 lead ECG data into a 3-D color coded map. 
The secondary objective of this study is to show the 
ability of 80 lead ECG to identify ST-segment eleva-
tion and depression during ischemic events.
case presentation
A 60 year old Caucasian male with complaints of 
chest pain and a positive stress test, underwent PCI 
and possible angiogram. The patient consented to 
be enrolled in this study, and the written consent 
was  obtained  from  the  patient.  The  patient  was 
connected  to  the  80  Lead  ECG  device  according 
to  company  instructions. The  angiogram  revealed 
90% blockage on proximal LAD coronary artery. A 
2.5 mm × 18 mm Xience stent was inserted. The use 
of the 80-lead ECG did not interfere with coronary 
artery  visualization  during  PCI. An  80  lead  ECG 
was recorded pre-catheterization, 30 seconds after 
balloon inflation, immediately after balloon defla-
tion,  and  30  seconds  after  stent  deployment. The 
duration of balloon inflation, balloon deflation, and 
stent deployment was equal (2 minutes each). No 
medications were given in between the first balloon 
inflation and the stent deployment. After the proce-
dure, the 80 lead ECGs were reviewed and analyzed 
by cardiologists. Interpreting the results of the body 
surface map requires some training. A green area 
represents an isoelectric state or no deflection from 
the  isoelectric  line  (the  isoelectric  line  indicates 
no voltage difference between the T and P wave in 
the subsequent beat). A red colored area indicates a 
positive deflection or deflection above the isoelec-
tric line and a blue area indicates a negative deflec-
tion or deflection below the isoelectric line. Figure 1 
represents the ST0 filter map which is a variation of 
the ST isopotential map that measures the voltage 
at the beginning of the ST segment or J point. This 
specialized  ST0  filter  map  displays  only  the  sig-
nificant ST-segment deflections and normalizes any 
small deflections that are likely artifacts or normal 
  variations. The thresholds for abnormal ST elevation 
or depression vary depending on the distance from 
the surface lead to the myocardium. Values exceed-
ing threshold are indicated as ±1.5 mm in the ante-
rior, septal and lateral walls, ±1.0 mm in the inferior 
wall, and ±0.5 mm in the posterior wall. The left 
box below each torso map indicates the maximum 
positive deflection in the respective recording and 
the right box below each map indicates the value 
of  the  maximum  negative  deflection.  In  the  pre-
  catheterization setting, there is no significant posi-
tive or negative deflection from baseline, as seen in 
Figure 1A. This can be appreciated both numerically 
by the values in the boxes (none exceeding thresh-
old values) and visually by the absence of signifi-
cant red or blue areas. When the balloon was inflated 
(Fig. 1B), there is marked significant positive eleva-
tion of 2.42 mm, also indicated by the bright red 
colored area in the upper anterior wall, indicating 
significant ischemia. When the balloon was deflated, 
there is no significant elevation as indicated by the 
1.47  mm  deviation  from  baseline  and  negative 
deflection of −0.25 mm, seen in Figure 1C. When 
the stent was deployed (Fig. 1D), there was a marked Visual evidence of ischemic preconditioning using 80-lead eCG
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decrease in the positive deflection from baseline as 
compared to when the balloon was inflated. In fact, 
the  maximum  recorded  baseline  deflection  when 
the stent was deployed was 0.96 mm, a value below 
significant threshold deviation. The 12 lead ECG at 
every phase was in accordance with the data of 80 
lead ECG. This can be evidence that the sublethal 
ischemic  insult  provided  by  the  balloon  inflation 
conditioned the myocardium to a subsequent isch-
emic event, in this case, the deployment of a stent.
Discussion
It is widely accepted that IPC provides protection to 
the myocardium. It has been proposed that pre-  infarct 
angina provides the sublethal insult which protects 
the myocardium from the subsequent infarct with 
Map 1: P0076_090520_091236_734 (05/20/09 09:12) Map 2: P0076_090520_091627_386 (05/20/09 09:16)
Map 3: P0076_090520_091710_778 (05/20/09 09:17) Map 4: P0076_090520_091822_691 (05/20/09 09:18)
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Figure 1. 80 lead ST0 filter map recordings during PCI. (A) In the pre-catheterization setting, there is no significant positive or negative deflection from 
baseline. (B) When the balloon was inflated, there is marked significant positive elevation of 2.42 mm, also indicated by the bright red colored area in the 
upper anterior wall, indicating significant ischemia. (c) When the balloon was deflated, there is no significant elevation as indicated by the 1.47 mm devia-
tion from baseline and negative deflection of −0.25 mm. (D) When the stent was deployed, there was a marked decrease in the positive deflection from 
baseline as compared to when the balloon was inflated.Dadkhah et al
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respect to the size of infarct, contractile dysfunction, 
arrhythmia generation and prognosis.6 IPC can be 
induced for myocardial protection prior to planned 
cases such as coronary artery bypass graft surgery 
(CABG).7 Monitoring and comparing the ischemic 
changes instantaneously during such procedures can 
provide significant information regarding regional 
myocardial injury or prognosis. Currently, the only 
device that allows visualization of ischemic changes 
is Heartscape Technologies 80 Lead ECG device. 
In contrast to the 12 leads of data and the limited 
anterior or front view of the heart from a traditional 
EKG, an 80 lead EKG utilizes 80 leads placed on 
both the front and back of the patient to analyze a 
360-degree spatial view of the heart. This system 
on  the  computer  console  displays  a  recognizable 
waveform from each single electrode position. The 
deviation of ST segments or the conduction patterns 
can be readily appreciated then by single lead repre-
sentations or by rhythm strips from each and every 
one of the 80 electrode positions. In addition, the 
system will configure any measurement of interest 
(ST segment at J-point, ST segment 60 ms, QRS 
deviations) as a color-coded precordial reconstitu-
tion  of  the  measurement  showing  the  location  of 
elevations or depressions, as color-coded hot spots 
or cold spots, located specifically in their lead posi-
tions relative to a human torso graphic. With this 
graphic in the actual device, as you point with a 
mouse towards any single spot, a hot spot or a cold 
spot, the waveform that measurement is originat-
ing from is displayed   instantaneously. Being first 
explained by Murry et al,8 IPC has been extremely 
investigated.  In  the  study  of Warren  et  al  it  was 
shown that IPC could be induced in 80% of elective 
PCI cases. In this study, it was also shown that, the 
frequency of post-procedural cardiac enzyme eleva-
tion, was significantly lower in patients experienc-
ing IPC. In addition, the risk of death and non-fatal 
MI at 1 year follow-up were reduced by 85%, and 
55% respectively, in patients who manifested IPC.9 
Recent studies on surgical models of cardioplegic 
arrest and reperfusion have suggested that, precon-
ditioned arrested heart may have an increased toler-
ance to prolonged ischemia and improved functional 
recovery after reperfusion.10 Mitochondrial adenos-
ine triphosphate-dependent potassium channel has 
been suggested as a “final common pathway”,11–13 
and  numerous  agonists  are  believed  to  medi-
ate their respective preconditioning effect via this 
  mechanism.14 To study IPC on humans, PCI model 
of coronary occlusion (brief myocardial ischemia) 
has been extensively used, whereas the use of ST 
segment deviation (in contrast to myocardial necro-
sis) has served as a surrogate marker of ischemic 
injury.6  To  our  best  knowledge,  despite  multiple 
studies on clinical aspects and molecular pathways 
of IPC, there has been no investigation to focus on 
the direct visualization of IPC during PCI. 
conclusion
In this study, we show that the 80 lead ECG device, 
can detect instantaneous ischemic changes. The util-
ity of 80 lead ECG body surface mapping is enor-
mous, when evaluating ischemic events.
Disclosures
Author(s) have provided signed confirmations to the 
publisher of their compliance with all applicable legal 
and ethical obligations in respect to declaration of 
conflicts of interest, funding, authorship and contrib-
utorship, and compliance with ethical requirements 
in  respect  to  treatment  of  human  and  animal  test 
subjects. If this article contains identifiable human 
subject(s) author(s) were required to supply signed 
patient consent prior to publication. Author(s) have 
confirmed that the published article is unique and not 
under consideration nor published by any other pub-
lication and that they have consent to reproduce any 
copyrighted material. The peer reviewers declared no 
conflicts of interest.
References
1.  Hoole SP, Heck PM, Sharples L, et al. Cardiac Remote Ischemic Precondi-
tioning in Coronary Stenting (CRISP Stent) Study: a prospective, random-
ized control trial. Circulation. 2009;119:820–7.
2.  Yang X, Cohen MV, Downey JM. Mechanism of cardioprotection by early 
ischemic preconditioning. Cardiovasc Drugs Ther. 2010;24:225–34.
3.  Ikonomidis  JS,  Weisel  RD,  Mickle  DA.  Ischemic  preconditioning: 
  cardioprotection for cardiac surgery. J Card Surg. 1994;9:526–31.
4.  Ali ZA, Callaghan CJ, Lim E, et al. Remote ischemic preconditioning reduces 
myocardial and renal injury after elective abdominal aortic aneurysm repair: 
a randomized controlled trial. Circulation. 2007;116:I98–105.
5.  Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: underlying mech-
anisms and clinical application. Cardiovasc Res. Aug 1, 2008;79(3):377–86.
6.  Miura T. Myocardial Response to Ischemic Preconditioning: Is it a Novel 
Predictor of Prognosis? JACC. 2003;42:1004–5.
7.  Tyagi P, Tayal G. Ischemic Preconditioning of Myocardium. Acta   Pharmacol 
Sin. 2002:865–70.publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  Yours!  You retain copyright
http://www.la-press.com
Visual evidence of ischemic preconditioning using 80-lead eCG
Clinical Medicine Insights: Case Reports 2011:4  61
  8.  Murry  CE,  Jennings  RB,  Reimer  KA.  Preconditioning  with    ischemia: 
a  delay  of  lethal  cell  injury  in  ischemic  myocardium.  Circulation. 
1986;74:1124–36.
  9.  Laskey WK, Beach D. Frequency and clinical significance of ischemic pre-
conditioning during percutaneous coronary intervention. J Am Coll Cardiol. 
2003;42:998–1003.
  10.  Ikonomidis JS, Weisel RD, Mickle DA. Ischemic preconditioning: cardio-
protection for cardiac surgery. J Card Surg. 1994;9:526–31.
  11.  Cohen MV, Baines CP, Downey JM. Ischemic preconditioning: from ade-
nosine receptor to KATP channel. Annu Rev Physiol. 2000;62:79–109.
  12.  Aguilar-Bryan L, Clement JP 4th, Gonzalez G, Kunjilwar K, Babenko A, 
Bryan J. Toward understanding the assembly and structure of KATP   channels. 
Physiol Rev. 1998;78:227–45.
  13.  Liu  Y,  Sato  T,  O’Rourke  B,  Marban  E.  Mitochondrial  ATP-dependent 
potassium  channels:  novel  effectors  of  cardioprotection?  Circulation. 
1998;97:2463–9.
  14.  Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, pre-
conditioning, and their clinical implications. Part 2. Circulation. 2001;104: 
3158–67.